01—Abstract
Summary
Summary of the 10-K filed February 19, 2010. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals' FY2009 10-K shows a company in heavy investment mode ahead of a potential 2011 launch of its lead hepatitis C drug candidate, telaprevir.
The company reported a net loss of $642.2 milliona ($3.71 per share) for 2009, up 40% from $459.9 million in 2008, as revenues fell 42% to $101.9 million on the absence of the large 2008 Janssen milestones. Management expects the 2010 net loss to exceed 2009's as it builds commercial supply and a sales force. Telaprevir's registration program (ADVANCE, ILLUMINATE, REALIZE) is fully enrolled, with SVR data expected in Q2 and Q3 2010, and an NDA planned for the second half of 2010.
Telaprevir is the single most important value driver, and the filing states that a significant portion of investor valuation rests on it. Liquidity improved substantially. Cash, equivalents and marketable securities rose to $1.28 billionb from $832 million, driven by roughly $801 million in net equity offerings, $155 million of secured 2012 Notes and $105 million from Mitsubishi Tanabe.
Management states current resources should fund operations for at least twelve months, but these are financing-dependent and the company warns it may need to raise more capital if telaprevir is materially delayed. Note the $155 millionc 2012 Notes and the $95 million sale of future Janssen milestones, which together tie up roughly $250 million of expected EU milestone cash. The pipeline extends beyond HCV: VX-770 (CF, G551D mutation) is in Phase 3 with a possible NDA in 2H 2011, while VX-222 and VX-759 (acquired via ViroChem for $100 million cash plus stock) carry $518.7 million of in-process R&D intangibles, about 80% attributed to VX-222.
Competitive risk is significant, since Merck's boceprevir could reach market on a similar timeline. The filing also flags a $7.2 milliond impairment on VCH-286 and the risk of larger future impairments on the ViroChem assets.
02—Key points
Key Highlights
- Net loss widened to $642.2M ($3.71/share) in 2009 from $459.9M in 2008; management expects the 2010 loss to be larger still as commercial launch preparations ramp up.
- Total revenues fell 42% to $101.9M, mainly because $55M of 2008 Janssen milestone revenue did not recur in 2009.
- Telaprevir (HCV protease inhibitor) is the lead asset: Phase 3 registration trials are fully enrolled, SVR data are expected in Q2–Q3 2010, the NDA is planned for 2H 2010, and US launch is targeted for 2011.
- Cash, equivalents and marketable securities reached $1.28B (up from $832M), supported by ~$801M of net equity raises and ~$250M of financing tied to Janssen milestones; management says this covers operations for at least 12 months.
- Competitive pressure is a key risk: Merck's boceprevir is on a comparable timeline and could launch in 2011.
- ViroChem acquisition added $518.7M of in-process R&D intangibles (about 80% tied to VX-222), creating meaningful impairment risk if clinical data disappoint.
- Convertible 2013 Notes were largely exchanged into equity during 2009 (outstanding principal cut from $287.5M to $32.1M), with the remainder to be redeemed in March 2010.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2009filed February 19, 2010Financial Statements
FY2009 against FY2008
| Line item | FY2009FY2008 | Change |
|---|---|---|
| Revenue | $101.89M$175.50M | −41.9% |
| R&D Expenses | $550.27M$516.91M | +6.5% |
| SG&A Expenses | $130.19M$101.29M | +28.5% |
| Operating Expenses | $715.90M$638.21M | +12.2% |
| Operating Income | -$614.01M-$462.71M | −32.7% |
| Interest Expense | $13.19M$13.47M | −2.1% |
| Net Income | -$642.18M-$459.85M | −39.6% |
| EPS (Basic) | $-3.71$-3.27 | −13.5% |
| EPS (Diluted) | $-3.71$-3.27 | −13.5% |
| Shares Outstanding (Basic) | 173.26M140.56M | +23.3% |
| Shares Outstanding (Diluted) | 173.26M140.56M | +23.3% |
05—Questions
Frequently Asked Questions
When could Vertex generate product revenue, and from what drug?
The company intends to submit an NDA for telaprevir in the US in the second half of 2010 and to begin US sales in 2011, assuming positive registration-trial results and FDA approval. VX-770 for cystic fibrosis could follow, with a potential NDA in the second half of 2011. The filing does not give a 2011 revenue estimate, and management says it does not expect any telaprevir sales revenue in 2010.
Is Vertex funded through the telaprevir launch?
Management says current cash, equivalents and marketable securities of about $1.28B should fund operations for at least the next twelve months. Beyond that, the company warns it may need additional capital, particularly if telaprevir is materially delayed, and it may have to curtail programs or give up rights to assets if funding is unavailable on acceptable terms.
What are the main risks to the telaprevir thesis?
Key risks include the outcome of the SVR data in 2010, FDA review of the NDA and manufacturing quality, safety issues such as severe rash seen in some trials, competition from Merck's boceprevir, possible reimbursement pressure, and dependence on collaborators Janssen and Mitsubishi Tanabe. Janssen can also terminate its agreement without cause on six months' notice.
Why did the net loss widen so much in 2009?
Revenue declined as 2008 included large milestone payments, while operating expenses rose to $715.9M. R&D grew to $550.3M, driven by workforce expansion and late-stage trials, and SG&A rose 29% to $130.2M as commercial build-out began. The loss also included $7.2M of ViroChem impairment, $7.8M of acquisition costs, and $18.1M of losses on note exchanges.
06—Continue